

CORRECTION TO APPENDIX 3H, Notification of Cessation of Securities

Aroa Biosurgery Ltd (ASX: ARX, 'AROA' or the 'Company') refers to the Appendix 3H, Notification of cessation of securities announced on 17 June 2025. The Company advises that this Appendix 3H contained a misclassification. Specifically, 245,955 securities were lapsed from ARXAAH when they should have been lapsed from ARXAAI. This is summarised in the table below:

ASX +security code	Security description	Incorrect number ceased	Correct number ceased	Correct total
ARXAAH	PERFORMANCE RIGHTS	245,955	0	961,255
ARXAAI	PERFORMANCE SHARE RIGHTS	0	245,955	2,761,917

All other cessations included in the Appendix 3H remain unchanged.

< ENDS >

Authorised on behalf of the Aroa Biosurgery Board of Directors by Brian Ward, CEO.

About Aroa Biosurgery:

Aroa Biosurgery is a soft-tissue regeneration company committed to 'unlocking regenerative healing for everybody'. We develop, manufacture, sell and distribute medical and surgical products to improve healing in complex wounds and soft tissue reconstruction. Our products are developed from a proprietary AROA ECM™ technology platform, a novel extracellular matrix biomaterial derived from ovine (sheep) forestomach. Over 7 million AROA products have been used globally in a range of procedures to date, with distribution into our key market of the United States via our direct sales force and our partner TELA Bio, Inc. Founded in 2008, AROA is headquartered in Auckland, New Zealand and is listed on the Australian Securities Exchange (ASX: ARX). www.aroa.com

Contacts

investor@aroa.com